Literature DB >> 7711428

Effectiveness of prophylactic therapy on goiter recurrence in an area with low iodine intake--a sonographic follow-up study.

A H Rzepka1, K Cissewski, T Olbricht, D Reinwein.   

Abstract

There is no agreement as to whether or not drug treatment after surgery for nodular goiter is effective in preventing recurrence of goiter. Data about recurrences in areas of marginally low iodine intake (like Germany) vary widely. Therefore, we performed a retrospective study in 104 patients who had been treated surgically because of benign uninodular or multinodular goiter. The mean follow-up period was 6.4 years (minimal 1 year) with at least three examinations. Thyroid ultrasound with volumetric analysis was recorded in each patient. Thirty-two patients did not receive any prophylaxis, 50 patients were treated with L-thyroxine, 17 patients with a combination of L-thyroxine and iodine and 5 patients with iodine alone. Recurrence of goiter was documented in 28.0% of the untreated patients and in 8.9% of the patients on prophylaxis (P < 0.05). The mean increase of thyroid volume was 7.3 ml versus 3.1 ml in patients without versus with prophylactic drug treatment (not significant). No significant correlation was found between the increase of thyroid volume and age of the patients, follow-up time, or initial thyroid volume, respectively. These data clearly demonstrate the effectiveness of prophylactic drug therapy to prevent recurrence of goiter after thyroid surgery in an iodine-deficient area.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7711428     DOI: 10.1007/bf00577737

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  21 in total

1.  Serum thyroglobulin concentration in nontoxic goiter and response to surgery with special reference to risk of goiter relapse.

Authors:  U Feldt-Rasmussen; M Blichert-Toft; J Date; V Haas
Journal:  World J Surg       Date:  1986-08       Impact factor: 3.352

2.  [Current aspects of prevention of struma recurrence].

Authors:  W Pimpl; R Rieger; H W Waclawiczek; O Boeckl
Journal:  Zentralbl Chir       Date:  1989       Impact factor: 0.942

3.  [Prevention of recurrences following thyroid gland surgery].

Authors:  H Steiner
Journal:  Wien Med Wochenschr       Date:  1977-03-15

4.  Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic scanning.

Authors:  H Perrild; J M Hansen; L Hegedüs; L Rytter; B Holm; E Gundtofte; K Johansen
Journal:  Acta Endocrinol (Copenh)       Date:  1982-07

5.  Nodular goiter--is thyroxine medication of any value?

Authors:  C P Persson; H Johansson; K Westermark; F A Karlsson
Journal:  World J Surg       Date:  1982-07       Impact factor: 3.352

6.  The value of L-thyroxine in the supressive therapy of euthyroid nodules and in the prevention of post-thyroidectomy recurrences.

Authors:  S Koloğlu; N Başkal; L B Koloğlu
Journal:  Endocrinologie       Date:  1988 Apr-Jun

7.  Recurrence of thyroid nodules after surgical removal in patients irradiated in childhood for benign conditions.

Authors:  L Fogelfeld; M B Wiviott; E Shore-Freedman; M Blend; C Bekerman; S Pinsky; A B Schneider
Journal:  N Engl J Med       Date:  1989-03-30       Impact factor: 91.245

8.  Postoperative goitre recurrence rate in Turkey.

Authors:  E Ibis; G Erbay; G Aras; A Akin
Journal:  Acta Endocrinol (Copenh)       Date:  1991-07

9.  Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre.

Authors:  A Berghout; W M Wiersinga; H A Drexhage; N J Smits; J L Touber
Journal:  Lancet       Date:  1990-07-28       Impact factor: 79.321

10.  Recurrence of nontoxic goitre with and without postoperative thyroxine medication.

Authors:  J P Geerdsen; L Frølund
Journal:  Clin Endocrinol (Oxf)       Date:  1984-11       Impact factor: 3.478

View more
  1 in total

1.  Thyroid nodules in recurrent multinodular goiters are predominantly polyclonal.

Authors:  P Harrer; M Broecker; A Zint; H Schatz; V Zumtobel; M Derwahl
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.